AXSM Axsome Therapeutics, Inc.

3.95
+0  (7%)
Previous Close 3.70
Open 3.75
Price To book 3.29
Market Cap 75.82M
Shares 19,196,000
Volume 298,802
Short Ratio 4.16
Av. Daily Volume 153,656

SEC filingsSee all SEC filings

  1. 8-K - Current report 17730779
  2. 8-K - Current report 17726141
  3. S-8 - Securities to be offered to employees in employee benefit plans 17722242
  4. 8-K - Current report 17705040
  5. 424B5 - Prospectus (Rule 424(b)(5)) 17703779

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 to be initiated 2Q 2017.
AXS-05
Agitation in patients with Alzheimer’s disease (AD)
Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 initiated March 2016. Top-line data due 1Q 2018.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 initiation contingent upon resources.
AXS-02
Chronic Low Back Pain Associated with Modic Changes

SEC Filings

  1. 8-K - Current report 17730779
  2. 8-K - Current report 17726141
  3. S-8 - Securities to be offered to employees in employee benefit plans 17722242
  4. 8-K - Current report 17705040
  5. 424B5 - Prospectus (Rule 424(b)(5)) 17703779
  6. 424B5 - Prospectus (Rule 424(b)(5)) 17702328
  7. 8-K - Current report 17686886
  8. 8-K - Current report 17672949
  9. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17672646
  10. 8-K - Current report 17609631